IMBiologics Corp. (KOSDAQ:493280)

Market Cap	212.46B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	14.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,007
Open	15,000
Previous Close	14,900
Day's Range	14,240 - 15,290
52-Week Range	13,190 - 104,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMBiologics

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 493280

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 22, 2026

Data Sources Report a data error